- Home
- SEMR vs VRDN Comparison
SEMR vs VRDN Comparison
Compare SEMR & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEMR
- VRDN
- Stock Information
- Founded
- SEMR 2008
- VRDN 2006
- Country
- SEMR United States
- VRDN United States
- Employees
- SEMR N/A
- VRDN N/A
- Industry
- SEMR EDP Services
- VRDN Medical Specialities
- Sector
- SEMR Technology
- VRDN Health Care
- Exchange
- SEMR Nasdaq
- VRDN Nasdaq
- Market Cap
- SEMR 1.3B
- VRDN 1.3B
- IPO Year
- SEMR 2021
- VRDN N/A
- Fundamental
- Price
- SEMR $9.41
- VRDN $17.80
- Analyst Decision
- SEMR Buy
- VRDN Strong Buy
- Analyst Count
- SEMR 8
- VRDN 11
- Target Price
- SEMR $17.00
- VRDN $38.50
- AVG Volume (30 Days)
- SEMR 798.5K
- VRDN 657.9K
- Earning Date
- SEMR 08-04-2025
- VRDN 08-07-2025
- Dividend Yield
- SEMR N/A
- VRDN N/A
- EPS Growth
- SEMR N/A
- VRDN N/A
- EPS
- SEMR 0.05
- VRDN N/A
- Revenue
- SEMR $396,021,000.00
- VRDN $302,000.00
- Revenue This Year
- SEMR $21.85
- VRDN N/A
- Revenue Next Year
- SEMR $18.50
- VRDN $17,102.33
- P/E Ratio
- SEMR $198.37
- VRDN N/A
- Revenue Growth
- SEMR 22.75
- VRDN 4.86
- 52 Week Low
- SEMR $7.90
- VRDN $9.90
- 52 Week High
- SEMR $18.74
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- SEMR 51.03
- VRDN 62.75
- Support Level
- SEMR $8.60
- VRDN $16.65
- Resistance Level
- SEMR $10.00
- VRDN $17.85
- Average True Range (ATR)
- SEMR 0.32
- VRDN 0.81
- MACD
- SEMR 0.09
- VRDN -0.01
- Stochastic Oscillator
- SEMR 57.14
- VRDN 64.73
About SEMR SEMrush Holdings Inc.
SEMrush Holdings Inc is engaged in the online visibility management software-as-a-service (SaaS) platform. Its platform utilizes data and intelligence at the core surrounded by AI-powered interconnected hubs focused on search engine optimization, paid advertising, social media management, local marketing, brand marketing, and content marketing Geographically, it generates revenues from the United States, the UK, and Others.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).